Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siri Ippagunta

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Biorxiv : the Preprint Server for Biology|August 30, 2024
Dominant Malignant Clones Leverage Lineage Restricted Epigenomic Programs to Drive Ependymoma DevelopmentAlisha Kardian, Hua Sun, Siri Ippagunta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune ResponseSanya Mehta, Siri Ippagunta, Srinidhi Varadharajan, et al.
Nature|March 26, 2026
Dominant clones leverage developmental epigenomic states to drive ependymomaAlisha S Kardian, Hua Sun, Siri Ippagunta, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Biorxiv : the Preprint Server for Biology|August 30, 2024
Dominant Malignant Clones Leverage Lineage Restricted Epigenomic Programs to Drive Ependymoma DevelopmentAlisha Kardian, Hua Sun, Siri Ippagunta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2025
B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune ResponseSanya Mehta, Siri Ippagunta, Srinidhi Varadharajan, et al.
Nature|March 26, 2026
Dominant clones leverage developmental epigenomic states to drive ependymomaAlisha S Kardian, Hua Sun, Siri Ippagunta, et al.
Pageof 1